Investigational drug · Phase 2
INO-5401
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Glioblastoma, Urothelial Carcinoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "INO-5401"
First trial start
2018
May 31, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INO-5401", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glioblastoma
- Urothelial Carcinoma
Approved drugs for the same conditions: Bladder and urothelial cancer · Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "INO-5401" as an intervention, largest first.
- INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)Active, not recruiting
Inovio PharmaceuticalsIndustry
NCT03491683 · 52 participants · Start May 31, 2018 · Primary completion Dec 31, 2027
Drug: INO-5401; INO-9012 and 2 more · For: Glioblastoma
Sites: Duarte, California; Palo Alto, California; San Francisco, California · 21 sites in all
- INO 5401 Vaccination in BRCA1/2 Mutation CarriersActive, not recruiting
University of PennsylvaniaAcademic, hospital or other
NCT04367675 · 44 participants (planned) · Start Apr 20, 2021 · Primary completion Dec 2026
Drug: INO-5401; INO-9012 · For: BRCA1/2 Mutation
Sites: Philadelphia, Pennsylvania
Inovio PharmaceuticalsIndustry
NCT03502785 · 35 participants · Start Jul 24, 2018 · Primary completion May 9, 2025
Drug: INO-5401; INO-9012 and 1 more · For: Urothelial Carcinoma
Sites: Phoenix, Arizona; Tampa, Florida; Baltimore, Maryland · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Shared epitopes create safety and efficacy concerns in several cancer vaccines.
Kellermann G, Mograbi B, Hofman P, et al. · J Immunother Cancer 2025
Also in development for Glioblastoma
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- L19TNFL19IL2, OnfekafuspPhase 310 trials
Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III
- VebreltinibPLB1001Phase 36 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, Glioblastoma, Non-Small Cell Lung Cancer
- VRT106Phase 33 trials
Guangzhou Virotech Pharmaceutical Co., Ltd. · Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC
- INO-9012Phase 24 trials
Geneos Therapeutics · HCC, Glioblastoma, Urothelial Carcinoma
- AL58805Phase 22 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- AzeliragonPhase 22 trials
Cantex Pharmaceuticals · Glioblastoma
- MT-125Phase 22 trials
Myosin Therapeutics Inc. · Glioblastoma (GBM), Glioblastoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.